Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

By J. Naidoo, D. Page, Bob T. Li, L. Connell, K. Schindler, M. Lacouture, M. Postow, J. Wolchok. Annals of Oncology, 2015

935 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials (2020, background): “Although immunotherapy against PD-1/PD-L1 has been applied in clinic, the use of monoclonal antibodies may affect the proliferation and activation of T cells, thereby trigger severe immune-related adverse reactions, including tissues damage, weaken the function of Fc-immune effect (killing immune ce”
Immune Checkpoint Inhibitors in Cancer Therapy (2022, background): “The toxicities corelated with PD-1/PD-L1 blockades were less severe compared to CTLA-4 inhibitors, and fatigue as the most common adverse event, occurring in 16–37% of patients receiving PD-1 inhibitor, and 12–24% of those who received PD-L1 inhibitor [147].”